Clinical Trials

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Other hematologic neoplasm

34 enrolled

Head & Neck

Thyroid Neoplasms

NCT03486873 2026-03-16

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Hematologic Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06253494 2026-03-03

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

60 enrolled

Endometrial Neoplasms

NCT05319730 2026-03-02

MK-3475-06B

230 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

18 enrolled

Endometrial Neoplasms

NCT05775159 2026-02-18

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

294 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06669572 2026-02-17

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04938817 2026-02-09

KEYNOTE-B98

110 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT07389629 2026-02-05

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

25 enrolled

Carcinoma, Renal Cell

NCT07359053 2026-01-22

MAGNATE-S

46 enrolled

Sarcoma

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

72 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell

NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

15 enrolled

Advanced Gastric Adenocarcinoma

NCT05286437 2025-12-30

LaPemERLA

40 enrolled

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT07081633 2025-12-30

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

30 enrolled

Uterine Cervical Neoplasms

NCT06880523 2025-12-18

SLIDE-HCC

140 enrolled

Carcinoma, Hepatocellular

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

144 enrolled

Carcinoma, Hepatocellular

NCT06110793 2025-12-17

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

49 enrolled

Breast Neoplasms

NCT04427293 2025-12-16

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

12 enrolled

Triple Negative Breast Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT06230471 2025-12-09

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

60 enrolled

Biliary Tract Neoplasms Immunotherapy

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07149090 2025-11-20

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

61 enrolled

Stomach Neoplasms

NCT04887805 2025-11-19

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT06962787 2025-11-17

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

260 enrolled

Kidney Neoplasms

NCT06858813 2025-11-10

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

232 enrolled

Liver Neoplasms

NCT05064280 2025-10-09

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

320 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05168163 2025-09-16

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

122 enrolled

Carcinoma, Hepatocellular

NCT05903833 2025-09-09

PIERCE

42 enrolled

Vulvar Neoplasms

NCT06374602 2025-09-05

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

20 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT06740370 2025-08-14

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Phase NA Recruiting

32 enrolled

Carcinoma, Hepatocellular

NCT07070700 2025-08-12

CASTLE-ZS-02

56 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

120 enrolled

Breast Neoplasms

NCT06892925 2025-07-10

Spring

59 enrolled

Biliary Tract Tumors

NCT07047586 2025-07-03

LEAF-01

146 enrolled

Carcinoma, Hepatocellular

NCT06157996 2025-05-30

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

92 enrolled

Stomach Neoplasms

NCT06318286 2025-05-25

PENINSULA

Other solid neoplasmThoracic

25 enrolled

Mesothelioma, Malignant

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

160 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06904196 2025-04-29

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

78 enrolled

Carcinoma, Hepatocellular

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Phase 3 Recruiting

480 enrolled

Cholangiocarcinoma

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

30 enrolled

Carcinoma, Hepatocellular

NCT06371157 2025-03-12

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Phase 3 Recruiting

469 enrolled